Management Comment "We believe these changes will position Sequenom to achieve higher levels of near-term performance while still allowing us to pursue our longer-term potential," said Sequenom President and CEO Dirk van den Boom. "We have the most comprehensive portfolio of products for noninvasive prenatal applications, a game changing new product in our MaterniT® GENOME laboratory-developed test, an experienced sales force, and an increased focus on serving physicians addressing average risk pregnancies. Because these advantages are considerable, it is essential for us to concentrate our resources on making the most of our opportunities in women's health."